CA-50 as tumour marker in transitional bladder carcinoma.
Monoclonal antibody CA-50 is a useful tumour marker in gastrointestinal carcinoma. We report an assessment of its value in bladder cancer patients. We found raised levels in 2 of 2 patients with infiltrating carcinoma and in 8 of 35 with superficial carcinoma. The recurrence rate was higher in patients with raised levels, since 6 of 8 with elevated levels and 15 of 27 with normal values had a recurrence within 6 months. T1 and T3 carcinoma had a mean CA-50 level higher than normal. G3 tumours had a mean level slightly above normal. A statistically significant difference emerged when comparing Ta with T1 + T3 carcinomas. A longer study, with serial determinations, could assess the role of CA-50 as a prognostic indicator in bladder cancer.
Tizzani
A
A
Institute of Nephro-urology, University of Turin, Italy.
Casetta
G
G
Piana
P
P
Piantino
P
P
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology
D015295:Antigens, Tumor-Associated, Carbohydrate